CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques

Journal of Leukocyte Biology

Volumn 79, Issue 2, 2006, Pages 257-267

  Teleshova, N ^a   Kenney, J ^a   Williams, V ^a   Van Nest, G ^b   Marshall, J ^b   Lifson, J D ^c   Sivin, I ^a   Dufour, J ^d   Bohm, R ^d   Gettie, A ^e   Pope, M ^a  

^a POPULATION COUNCIL   (United States)

^b Dynavax Technologies Corporation   (United States)

^c SAIC FREDERICK INC   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

B lymphocyte; Immunostimulation; Primate; SIV

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD20 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; 1018 OLIGONUCLEOTIDE; C274 OLIGONUCLEOTIDE; CD40 LIGAND; CHEMOKINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; OLIGONUCLEOTIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CELL SUSPENSION; CELL VIABILITY; CHRONIC DISEASE; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; ANIMAL; B LYMPHOCYTE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; MACACA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CD40 LIGAND; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; MACACA MULATTA; MALE; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33646446665     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0205084     Document Type: Article

References (89)

1. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T. C., Ruprecht, R. M. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206.
2. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., Lewis, M. G. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210.
3. Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., Burton, D. R. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347.
4. Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J., Burton, D. R., Moore, J. P. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346.
5. Berzofsky, J. A., Terabe, M., Oh, S., Belyakov, I. M., Ahlers, J. D., Janik, J. E., Morris, J. C. (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113, 1515-1525.
6. Belyakov, I. M., Berzofsky, J. A. (2004) Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20, 247-253.
7. Pantaleo, G., Koup, R. A. (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10, 806-810.
8. Goulder, P. J., Watkins, D. I. (2004) HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4, 630-640.
9. Letvin, N. L. (2005) Progress toward an HIV vaccine. Annu. Rev. Med. 56, 213-223.
10. Dal Porto, J. M., Gauld, S. B., Merrell, K. T., Mills, D., Pugh-Bernard, A. E., Cambier, J. (2004) B cell antigen receptor signaling 101. Mol. Immunol. 41, 599-613.
11. Tangye, S. G., Hodgkin, P. D. (2004) Divide and conquer: the importance of cell division in regulating B-cell responses. Immunology 112, 509-520.
12. Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H., Fauci, A. S. (1983) Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309, 453-458.
13. Pahwa, S. G., Quilop, M. T., Lange, M., Pahwa, R. N., Grieco, M. H. (1984) Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 757-763.
14. Katz, I. R., Krown, S. E., Safai, B., Oettgen, H. F., Hoffmann, M. K. (1986) Antigen-specific and polyclonal B-cell responses in patients with acquired immunodeficiency disease syndrome. Clin. Immunol. Immunopathol. 39, 359-367.
15. Gaidano, G., Capello, D., Carbone, A. (2000) The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin. Oncol. 27, 431-441.
16. Amadori, A., De Rossi, A., Faulkner-Valle, G. P., Chieco-Bianchi, L. (1988) Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin. Immunol. Immunopathol. 46, 342-351.
17. Martinez-Maza, O., Crabb, E., Mitsuyasu, R. T., Fahey, J. L., Giorgi, J. V. (1987) Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J. Immunol. 138, 3720-3724.
18. Moir, S., Malaspina, A., Ogwaro, K. M., Donoghue, E. T., Hallahan, C. W., Ehler, L. A., Liu, S., Adelsberger, J., Lapointe, R., Hwu, P., Baseler, M., Orenstein, J. M., Chun, T. W., Mican, J. A., Fauci, A. S. (2001) HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. USA 98, 10362-10367.
19. Fournier, A. M., Fondere, J. M., Alix-Panabieres, C., Merle, C., Baillat, V., Huguet, M. F., Taib, J., Ohayon, V., Zembala, M., Reynes, J., Vendrell, J. P. (2002) Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells. Clin. Immunol. 103, 98-109.
20. Shirai, A., Cosentino, M., Leitman-Klinman, S. F., Klinman, D. M. (1992) Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J. Clin. Invest. 89, 561-566.
21. Ammann, A. J., Schiffman, G., Abrams, D., Volberding, P., Ziegler, J., Conant, M. (1984) B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 251, 1447-1449.
22. Schnittman, S. M., Lane, H. C., Higgins, S. E., Folks, T., Fauci, A. S. (1986) Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 233, 1084-1086.
23. Chirmule, N., Oyaizu, N., Kalyanaraman, V. S., Pahwa, S. (1992) Inhibition of normal B-cell function by human immunodeficiency virus envelope glycoprotein, gp120. Blood 79, 1245-1254.
24. Boue, F., Wallon, C., Goujard, C., Barre-Sinoussi, F., Galanaud, P., Delfraissy, J-F. (1992) HIV induces IL-6 production by human B lymphocytes role of IL-4. J. Immunol. 148, 3761-3767.
25. Delfraissy, J. F., Wallon, C., Boue, F., Barresinoussi, F., Galanaud, P. (1991) Tumor necrosis factor-α inhibits the competence signal delivered by HIV to normal B cells. J. Immunol. 146, 1516-1521.
26. Roman, M., Orozco-Martin, E., Goodman, J. S., Nguyen, M-D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., Raz, E. (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3, 849-854.
27. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., Harding, C. V. (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (TH1) immunity. J. Exp. Med. 186, 1623-1631.
28. Sun, S., Kishimoto, H., Sprent, J. (1998) DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J. Exp. Med. 187, 1145-1150.
29. Moldoveanu, Z., Love-Homan, L., Huang, W. Q., Krieg, A. M. (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216-1224.
30. Klinman, D. M. (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-258.
31. Klinman, D. M., Currie, D., Gursel, I., Verthelyi, D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.
32. Iwasaki, A., Medzhitov, R. (2004) Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995.
33. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., Hartmann, G. (2002) Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531-4537.
34. He, B., Qiao, X., Cerutti, A. (2004) CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 173, 4479-4491.
35. Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
36. Ashkar, A. A., Rosenthal, K. L. (2002) Toll-like receptor 9, CpG DNA and innate immunity. Curr. Mol. Med. 2, 545-556.
37. Marshall, J. D., Fearon, K., Abbate, C., Subramanian, S., Yee, P., Gregorio, J., Coffman, R. L., Van Nest, G. (2003) Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73, 781-792.
38. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rassmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., Krieg, A. M. (2000) Delineation of a CpG phosphorothionate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617-1624.
39. Verthelyi, D., Zeuner, R. A. (2003) Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24, 519-522.
40. Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A. M., Hartmann, G. (2001) Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026-3037.
41. Kadowaki, N., Antonenko, S., Liu, Y. J. (2001) Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166, 2291-2295.
42. Kadowaki, N., Ho, S., Antonenko, S., Malefyt, R. W., Kastelein, R. A., Bazan, F., Liu, Y. J. (2001) Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869.
43. Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., Belardelli, F. (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191, 1777-1788.
44. Biron, C. A. (2001) Interferons α and β as immune regulators - a new look. Immunity 14, 661-664.
45. Santini, S. M., Di Pucchio, T., Lapenta, C., Parlato, S., Logozzi, M., Belardelli, F. (2003) A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 21, 357-362.
46. Lapenta, C., Santini, S. M., Logozzi, M., Spada, M., Andreotti, M., Di Pucchio, T., Parlato, S., Belardelli, F. (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. 198, 361-367.
47. Carbonneil, C., Aouba, A., Burgard, M., Cardinaud, S., Rouzioux, C., Langlade-Demoyen, P., Weiss, L. (2003) Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-α are potent inducers of HIV-specific CD8 T cells. AIDS 17, 1731-1740.
48. Mattei, F., Schiavoni, G., Belardelli, F., Tough, D. F. (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179-1187.
49. Cella, M., Facchetti, F., Lanzavecchia, A., Colonna, M. (2000) Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Th1 polarization. Nat. Immunol. 1, 305-310.
50. Liu, Y. J. (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259-262.
51. Fayette, J., Dubois, B., Vandenabelle, S., Bridon, J-M., Vanbervliet, B., Durand, I., Banchereau, J., Caux, C., Briere, F. (1997) Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J. Exp. Med. 185, 1909-1918.
52. MacLennan, I., Vinuesa, C. (2002) Dendritic cells, BAFF, and APRIL. Innate players in adaptive antibody responses. Immunity 17, 235-238.
53. Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., Tough, D. F. (2001) Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470.
54. Colino, J., Shen, Y., Snapper, C. M. (2002) Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharidespecific immunoglobulin isotype responses in vivo through distinct mechanisms. J. Exp. Med. 195, 1-13.
55. Jego, G., Pascual, V., Palucka, A. K., Banchereau, J. (2005) Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. 8, 124-139.
56. Craxton, A., Magaletti, D., Ryan, E. J., Clark, E. A. (2003) Macrophage-and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101, 4464-4471.
57. Balazs, M., Martin, F., Zhou, T., Kearney, J. (2002) Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17, 341-352.
58. Litinskiy, M. B., Nardelli, B., Hilbert, D. M., He, B., Schaffer, A., Casali, P., Cerutti, A. (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3, 822-829.
59. Jego, G., Palucka, A. K., Blanck, J-P., Chalouni, C., Pascual, V., Banchereau, J. (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225-234.
60. Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., Rothenfusser, S., Endres, S. (2003) Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633-1641.
61. Poeck, H., Wagner, M., Battiany, J., Rothenfusser, S., Wellisch, D., Hornung, V., Jahrsdorfer, B., Giese, T., Endres, S., Hartmann, G. (2004) Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103, 3058-3064.
62. Desrosiers, R. C. (1990) The simian immunodeficiency viruses. Annu. Rev. Immunol. 8, 557-578.
63. Teleshova, N., Kenney, J., Jones, J., Marshall, J., Van Nest, G., Dufour, J., Bohm, R., Lifson, J. D., Gettie, A., Pope, M. (2004) CpG-C ISS-ODN activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-γ-secreting SIV-specific T cells. J. Immunol. 173, 1647-1657.
64. Harouse, J. M., Gettie, A., Tan, R. C., Blanchard, J., Cheng-Mayer, C. (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816-819.
65. Tan, R. C., Harouse, J. M., Gettie, A., Cheng-Mayer, C. (1999) In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J. Med. Primatol. 28, 164-168.
66. Harouse, J. M., Gettie, A., Eshetu, T., Tan, R. C., Bohm, R., Blanchard, J., Baskin, G., Cheng-Mayer, C. (2001) Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75, 1990-1995.
67. Hsu, M., Harouse, J. M., Gettie, A., Buckner, C., Blanchard, J., Cheng-Mayer, C. (2003) Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J. Virol. 77, 989-998.
68. Clark, E. A., Draves, K. E. (1987) Activation of macaque T cells and B cells with agonistic monoclonal antibodies. Eur. J. Immunol. 17, 1799-1805.
69. Chertova, E., Bess Jr, J. W., Crise, B. J., Sowder, I. R., Schaden, T. M., Hilburn, J. M., Hoxie, J. A., Benveniste, R. E., Lifson, J. D., Henderson, L. E., Arthur, L. O. (2002) Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76, 5315-5325.
70. Bess Jr., J. W., Gorelick, R. J., Bosche, W. J., Henderson, L. E., Arthur, L. O. (1997) Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230, 134-144.
71. Frank, I., Piatak, M. J., Stoessel, H., Romani, N., Bonnyay, D., Lifson, J. D., Pope, M. (2002) Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J. Virol. 76, 2936-2951.
72. Verthelyi, D., Wang, V. W., Lifson, J. D., Klinman, D. M. (2004) CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 18, 1003-1008.
73. Klinman, D. M., Xie, H., Little, S. F., Currie, D., Ivins, B. E. (2004) CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22, 2881-2886.
74. Cafaro, A., Titti, F., Fracasso, C., Maggiorella, M. T., Baroncelli, S., Caputo, A., Goletti, D., Borsetti, A., Pace, M., Fanales-Belasio, E., Ridolfi, B., Negri, D. R., Sernicola, L., Belli, R., Corrias, F., Macchia, I., Leone, P., Michelini, Z., ten Haaft, P., Butto, S., Verani, P., Ensoli, B. (2001) Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19, 2862-2877.
75. Verthelyi, D., Gursel, M., Kenney, R. T., Lifson, J. D., Liu, S., Mican, J., Klinman, D. M. (2003) CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170, 4717-4723.
76. Marshall, J. D., Fearon, K. L., Higgins, D., Hessel, E. M., Kanzler, H., Abbate, C., Yee, P., Gregorio, J., Cruz, T. D., Lizcano, J. O., Zolotorev, A., McClure, H. M., Brasky, K. M., Murthy, K. K., Coffman, R. L., Nest, G. V. (2005) Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24, 63-72.
77. Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D., Hermine, O., Tough, D. F., Kaveri, S. V. (2005) Modulation of dendritic cell maturation and function by B lymphocytes. J. Immunol. 175, 15-20.
78. Teleshova, N., Frank, I., Pope, M. (2003) Immunodeficiency virus exploitation of dendritic cells in the early steps of infection. J. Leukoc. Biol. 74, 683-690.
79. Rinaldo Jr., C. R., Piazza, P. (2004) Virus infection of dendritic cells: portal for host invasion and host defense. Trends Microbiol. 12, 337-345.
80. Messmer, D., Jacqué, J-M., Santisteban, C., Bristow, C., Han, S-Y., Villamide-Herrera, L., Mehlhop, E., Marx, P. A., Steinman, R. M., Gettie, A., Pope, M. (2002) Nef uncouples dendritic cell phenotypic maturation from cytokine and chemokine secretion. J. Immunol. 169, 4172-4182.
81. Swingler, S., Brichacek, B., Jacque, J., Ulich, C., Zhou, J., Stevenson, M. (2003) HIV-1 Nef intersects the CD40L signaling pathway in macrophages to promote resting cell infection. Nature 424, 213-219.
82. Rossio, J. L., Esser, M. T., Suryanarayana, K., Schneider, D. K., Bess Jr., J. W., Vasquez, G. M., Wiltrout, T. A., Chertova, E., Grimes, M. K., Sattentau, Q., Arthur, L. O., Henderson, L. E., Lifson, J. D. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72, 7992-8001.
83. Hirano, T. (1998) Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16, 249-284.
84. Kimata, H., Yoshida, A., Ishioka, C., Fujimoto, M., Lindley, I., Furusho, K. (1996) RANTES and macrophage inflammatory protein 1 α selectively enhance immunoglobulin (IgE) and IgG4 production by human B cells. J. Exp. Med. 183, 2397-2402.
85. Sims-Mourtada, J. C., Guzman-Rojas, L., Rangel, R., Nghiem, D. X., Ullrich, S. E., Guret, C., Cain, K., Martinez-Valdez, H. (2003) In vivo expression of interleukin-8, and regulated on activation, normal, T-cell expressed, and secreted, by human germinal centre B lymphocytes. Immunology 110, 296-303.
86. Corcione, A., Tortolina, G., Bonecchi, R., Battilana, N., Taborelli, G., Malavasi, F., Sozzani, S., Ottonello, L., Dallegri, F., Pistoia, V. (2002) Chemotaxis of human tonsil B lymphocytes to CC chemokine receptor (CCR) 1, CCR2 and CCR4 ligands is restricted to non-germinal center cells. Int. Immunol. 14, 883-892.
87. Yonezawa, A., Morita, R., Takaori-Kondo, A., Kadowaki, N., Kitawaki, T., Hori, T., Uchiyama, T. (2003) Natural α interferon-producing cells respond to human immunodeficiency virus type 1 with α interferon production and maturation into dendritic cells. J. Virol. 77, 3777-3784.
88. Patterson, S., Rae, A., Hockey, N., Gilmour, J., Gotch, F. (2001) Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J. Virol. 75, 6710-6713.
89. Teleshova, N., Kenney, J., Van Nest, G., Marshall, J., Lifson, J. D., Sivin, I., Dufour, J., Bohm, R., Gettie, A., Pope, M. (2005) In vivo CpG-C ISS-ODN activation of lymph node dendritic cells and B cells in naïve and SHIV-infected macaques, submitted.